Abstract
Background: It is known that calcium channel blockers are associated with a risk of gingival hyperplasia. These drugs are widely used in the management of gestational hypertensive disorders.
Case: A 27-year-old G1 woman presented with gingival hyperplasia at 27 weeks gestation during a hospitalisation for preeclampsia. She had been on nifedipine for hypertension for the last 9 weeks. Nifedipine was discontinued and replaced by methyldopa and already after 48 hours the gingival hyperplasia improved. She delivered two weeks later and the gingival hyperplasia resolved completely without surgical intervention. The Naranjo’s score was used to prove the nifedipine’s imputability. Conclusion: This first case report of gingival hyperplasia induced by nifedipine in pregnancy could be used as a reference for clinicians in the management of this adverse effect during the pregnancy.Keywords: Calcium channel blockers, dental management, gingival hyperplasia, nifedipine, preeclampsia, pregnancy.
Current Drug Safety
Title:Nifedipine Induced Gingival Hyperplasia in Pregnancy: A Case Report
Volume: 12 Issue: 1
Author(s): Brochet M.S., Harry M. and Morin F.
Affiliation:
Keywords: Calcium channel blockers, dental management, gingival hyperplasia, nifedipine, preeclampsia, pregnancy.
Abstract: Background: It is known that calcium channel blockers are associated with a risk of gingival hyperplasia. These drugs are widely used in the management of gestational hypertensive disorders.
Case: A 27-year-old G1 woman presented with gingival hyperplasia at 27 weeks gestation during a hospitalisation for preeclampsia. She had been on nifedipine for hypertension for the last 9 weeks. Nifedipine was discontinued and replaced by methyldopa and already after 48 hours the gingival hyperplasia improved. She delivered two weeks later and the gingival hyperplasia resolved completely without surgical intervention. The Naranjo’s score was used to prove the nifedipine’s imputability. Conclusion: This first case report of gingival hyperplasia induced by nifedipine in pregnancy could be used as a reference for clinicians in the management of this adverse effect during the pregnancy.Export Options
About this article
Cite this article as:
M.S. Brochet, M. Harry and F. Morin, Nifedipine Induced Gingival Hyperplasia in Pregnancy: A Case Report, Current Drug Safety 2017; 12 (1) . https://dx.doi.org/10.2174/1574886311666160426141851
DOI https://dx.doi.org/10.2174/1574886311666160426141851 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genes, Environment, and Interactions in Prevention of Type 2 Diabetes: A Focus on Physical Activity and Lifestyle Changes
Current Molecular Medicine Preventive and Therapeutic Potentials of Anthocyanins in Diabetes and Associated Complications
Current Medicinal Chemistry Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews A Review of Oxidative Stress Related Genes and New Antioxidant Therapy in Diabetic Nephropathy
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response
Current Psychiatry Reviews Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Assessing Systemic Arterial Hypertension Through Echocardiography: A Review for the Clinician
Current Hypertension Reviews Glucokinase Activators for the Potential Treatment of Type 2 Diabetes
Current Topics in Medicinal Chemistry UGT1A1 Mediated Drug Interactions and its Clinical Relevance
Current Drug Metabolism Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets Enhancement of the Pharmacological Efficacy of FGF-21 by Genetic Modification and PEGylation
Current Pharmaceutical Biotechnology Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds Post-translational Modifications of Proteins: Biomarkers and Therapeutic Targets for Diabetes Related Complications
Current Proteomics Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine Glucose Transporter and Na+ / glucose Cotransporter as Molecular Targets of Anti-Diabetic Drugs
Current Medicinal Chemistry Resistant Hypertension in the Elderly-Second Line Treatments: Aldosterone Antagonists, Central Alpha-Agonist Agents, Alpha-Adrenergic Receptor Blockers, Direct Vasodilators, and Exogenous Nitric Oxide Donors
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Endophthalmitis
Anti-Infective Agents in Medicinal Chemistry Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery